Matthew Tunis
Overview
Explore the profile of Matthew Tunis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ximenes R, Simmons A, Gebretekle G, Nam A, Wong E, Salvadori M, et al.
Vaccine
. 2025 Mar;
54:126985.
PMID: 40054141
Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). Objective: To assess the cost-effectiveness of PCV21 compared to current...
2.
Simmons A, Gebretekle G, Pless R, Wierzbowski A, Tunis M, Tuite A
Can Commun Dis Rep
. 2025 Feb;
51(2-3):68-83.
PMID: 39980573
Background: Two pneumococcal conjugate vaccines, covering 15 and 20 serotypes (Pneu-C-15 and Pneu-C-20, respectively), were recently approved for use in the Canadian paediatric population. Objective: To assess the cost-effectiveness of...
3.
Montroy J, Yan C, Khan F, Forbes N, Krishnan R, Tunis M, et al.
Vaccine
. 2025 Jan;
47:126706.
PMID: 39787800
Background: In susceptible individuals, post-exposure prophylaxis (PEP) is often recommended following exposure to measles, however the data that these recommendations are based on are limited. The objective of this systematic...
4.
Lim S, Hersi M, Krishnan R, Montroy J, Rook B, Farrah K, et al.
Vaccine X
. 2024 Nov;
21:100575.
PMID: 39555243
Background: The COVID-19 pandemic resulted in a rapid accumulation of novel vaccine research evidence. As a means to monitor this evidence, the Public Health Agency of Canada (PHAC) created the...
5.
Fakhraei R, Fell D, El-Chaar D, Thampi N, Sander B, Brown K, et al.
Lancet Reg Health Am
. 2024 Nov;
39:100914.
PMID: 39507368
Background: Group B (GBS) significantly contributes to neonatal sepsis and meningitis, with varying disease rates reported globally and limited population-based data. We estimated infant GBS disease burden in Ontario, Canada...
6.
Doyon-Plourde P, Farley R, Krishnan R, Tunis M, Wallace M, Zafack J
Vaccine
. 2024 Oct;
42(26):126406.
PMID: 39388931
Introduction: The balance of benefits and harms of vaccines are assessed by regulatory agencies and National Immunization Technical Advisory Groups (NITAGs) to inform vaccine authorization or guidance. The Grading of...
7.
Tuite A, Simmons A, Rudd M, Cernat A, Gebretekle G, Yeung M, et al.
CMAJ
. 2024 Sep;
196(29):E989-E1005.
PMID: 39251240
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the cost-effectiveness of different age cut-offs...
8.
Gebretekle G, Yeung M, Ximenes R, Cernat A, Simmons A, Killikelly A, et al.
Vaccine
. 2024 Jul;
42(21):126164.
PMID: 39079810
Background: Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease. Objective: Assess the cost-effectiveness of RSVpreF and nirsevimab programs in...
9.
Montroy J, Salvadori M, Forbes N, Dubey V, Almasri S, Jirovec A, et al.
Can Commun Dis Rep
. 2024 Jul;
50(6):166-178.
PMID: 39021378
Background: Current National Advisory Committee on Immunization (NACI) guidance recommends human papillomavirus (HPV) vaccines be administered as a two or three-dose schedule. Recently, several large clinical trials have reported the...
10.
Tuite A, Ng V, Ximenes R, Diener A, Rafferty E, Ogden N, et al.
Can Commun Dis Rep
. 2024 Mar;
49(6):263-273.
PMID: 38440772
Background: Vaccination has been a key part of Canada's coronavirus disease 2019 (COVID-19) pandemic response. Although the clinical benefits of vaccination are clear, an understanding of the population-level benefits of...